JP2005507637A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005507637A5 JP2005507637A5 JP2002568744A JP2002568744A JP2005507637A5 JP 2005507637 A5 JP2005507637 A5 JP 2005507637A5 JP 2002568744 A JP2002568744 A JP 2002568744A JP 2002568744 A JP2002568744 A JP 2002568744A JP 2005507637 A5 JP2005507637 A5 JP 2005507637A5
- Authority
- JP
- Japan
- Prior art keywords
- propeptide
- modified
- gdf
- pharmaceutical composition
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 73
- 108010056852 Myostatin Proteins 0.000 claims 73
- 239000008194 pharmaceutical composition Substances 0.000 claims 54
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims 53
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 claims 53
- 150000007523 nucleic acids Chemical class 0.000 claims 39
- 108020004707 nucleic acids Proteins 0.000 claims 36
- 102000039446 nucleic acids Human genes 0.000 claims 36
- 125000003275 alpha amino acid group Chemical group 0.000 claims 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 21
- 208000035475 disorder Diseases 0.000 claims 21
- 230000000087 stabilizing effect Effects 0.000 claims 21
- 102000009027 Albumins Human genes 0.000 claims 14
- 108010088751 Albumins Proteins 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 239000002299 complementary DNA Substances 0.000 claims 12
- 230000035772 mutation Effects 0.000 claims 12
- 239000002773 nucleotide Substances 0.000 claims 12
- 125000003729 nucleotide group Chemical group 0.000 claims 12
- 230000006337 proteolytic cleavage Effects 0.000 claims 12
- 238000000338 in vitro Methods 0.000 claims 8
- 238000001727 in vivo Methods 0.000 claims 8
- 125000000837 carbohydrate group Chemical group 0.000 claims 7
- 230000013595 glycosylation Effects 0.000 claims 7
- 238000006206 glycosylation reaction Methods 0.000 claims 7
- 235000018102 proteins Nutrition 0.000 claims 7
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 108091034117 Oligonucleotide Proteins 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 6
- 208000021642 Muscular disease Diseases 0.000 claims 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 5
- 208000030159 metabolic disease Diseases 0.000 claims 5
- 201000006938 muscular dystrophy Diseases 0.000 claims 5
- 208000018360 neuromuscular disease Diseases 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 229920000642 polymer Polymers 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 206010002329 Aneurysm Diseases 0.000 claims 3
- 206010006895 Cachexia Diseases 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 208000026062 Tissue disease Diseases 0.000 claims 3
- 210000000577 adipose tissue Anatomy 0.000 claims 3
- 210000000988 bone and bone Anatomy 0.000 claims 3
- 230000003412 degenerative effect Effects 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000003387 muscular Effects 0.000 claims 3
- 201000000585 muscular atrophy Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 238000000746 purification Methods 0.000 claims 3
- 208000001076 sarcopenia Diseases 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 201000009623 Myopathy Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26750901P | 2001-02-08 | 2001-02-08 | |
| PCT/US2002/003467 WO2002068650A2 (en) | 2001-02-08 | 2002-02-08 | Modified and stabilized gdf propeptides and uses thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005209321A Division JP2006001938A (ja) | 2001-02-08 | 2005-07-19 | 改変され安定化されたｇｄｆプロペプチドおよびその使用 |
| JP2008298812A Division JP5013618B2 (ja) | 2001-02-08 | 2008-11-21 | 改変され安定化されたｇｄｆプロペプチドおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005507637A JP2005507637A (ja) | 2005-03-24 |
| JP2005507637A5 true JP2005507637A5 (https=) | 2006-01-05 |
| JP4280071B2 JP4280071B2 (ja) | 2009-06-17 |
Family
ID=23019083
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002568744A Expired - Fee Related JP4280071B2 (ja) | 2001-02-08 | 2002-02-08 | 改変され安定化されたｇｄｆプロペプチドおよびその使用 |
| JP2005209321A Withdrawn JP2006001938A (ja) | 2001-02-08 | 2005-07-19 | 改変され安定化されたｇｄｆプロペプチドおよびその使用 |
| JP2008298812A Expired - Fee Related JP5013618B2 (ja) | 2001-02-08 | 2008-11-21 | 改変され安定化されたｇｄｆプロペプチドおよびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005209321A Withdrawn JP2006001938A (ja) | 2001-02-08 | 2005-07-19 | 改変され安定化されたｇｄｆプロペプチドおよびその使用 |
| JP2008298812A Expired - Fee Related JP5013618B2 (ja) | 2001-02-08 | 2008-11-21 | 改変され安定化されたｇｄｆプロペプチドおよびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US7202210B2 (https=) |
| EP (1) | EP1397492B1 (https=) |
| JP (3) | JP4280071B2 (https=) |
| AR (1) | AR032567A1 (https=) |
| AT (1) | ATE357519T1 (https=) |
| AU (1) | AU2002243852B2 (https=) |
| BR (1) | BR0207110A (https=) |
| CA (2) | CA2437218A1 (https=) |
| CL (1) | CL2009000648A1 (https=) |
| CY (1) | CY1106629T1 (https=) |
| DE (1) | DE60219006T2 (https=) |
| DK (1) | DK1397492T3 (https=) |
| ES (1) | ES2284828T3 (https=) |
| MX (1) | MXPA03007063A (https=) |
| NO (1) | NO333427B1 (https=) |
| NZ (2) | NZ527286A (https=) |
| PL (2) | PL212078B1 (https=) |
| PT (1) | PT1397492E (https=) |
| SG (2) | SG165982A1 (https=) |
| TW (2) | TWI329129B (https=) |
| WO (1) | WO2002068650A2 (https=) |
| ZA (2) | ZA200508954B (https=) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| BR0307871A (pt) | 2002-02-21 | 2005-04-12 | Wyeth Corp | Proteìnas contendo domìnio de folistatina |
| CA2476887A1 (en) | 2002-02-21 | 2003-09-04 | Wyeth | Gasp1:a follistatin domain containing protein |
| EP2192129A1 (en) * | 2002-09-16 | 2010-06-02 | Johns Hopkins University | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| AR047392A1 (es) * | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| CA2524255C (en) | 2003-03-21 | 2014-02-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| BRPI0410927A (pt) * | 2003-06-02 | 2006-06-27 | Wyeth Corp | métodos terapêuticos e profiláticos para distúrbios neuromusculares |
| EP1771470B1 (en) * | 2004-07-23 | 2013-06-26 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| AU2005272646A1 (en) * | 2004-08-12 | 2006-02-23 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors |
| TWI364458B (en) | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
| TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
| TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
| US8088508B2 (en) | 2005-01-31 | 2012-01-03 | Panasonic Corporation | Thermal battery |
| US20060216279A1 (en) * | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
| CA2601667A1 (en) * | 2005-03-23 | 2006-09-28 | Wyeth | Detection of gdf-8 modulating agents |
| AU2006232914A1 (en) * | 2005-03-23 | 2006-10-12 | Wyeth | Detection of an immune response to GDF-8 modulating agents |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| KR20190006086A (ko) * | 2005-11-23 | 2019-01-16 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도 |
| US20070190056A1 (en) * | 2006-02-07 | 2007-08-16 | Ravi Kambadur | Muscle regeneration compositions and uses therefor |
| CA2655933C (en) * | 2006-06-23 | 2014-09-09 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
| AU2007282224B2 (en) | 2006-08-11 | 2013-08-29 | Vico Therapeutics B.V. | Methods and means for treating DNA repeat instability associated genetic disorders |
| US8895016B2 (en) * | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| DK2124999T3 (da) * | 2006-12-18 | 2013-01-14 | Acceleron Pharma Inc | Activin-actrii antagonister og anvendelser til behandling af anæmi |
| EP2111229B1 (en) * | 2007-02-01 | 2013-04-10 | Acceleron Pharma, Inc. | Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss |
| TWI782836B (zh) * | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| ES2756725T3 (es) * | 2007-02-09 | 2020-04-27 | Acceleron Pharma Inc | Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA |
| WO2009008727A2 (en) * | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs or tissues |
| CA2693742A1 (en) * | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| JP2010535708A (ja) | 2007-08-03 | 2010-11-25 | ビオマリン アイジーエー リミテッド | デュシェンヌ型筋ジストロフィーの治療のための薬物併用 |
| EP3243524A1 (en) * | 2007-09-18 | 2017-11-15 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
| AU2008317566B2 (en) | 2007-10-26 | 2014-05-01 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| NZ587178A (en) * | 2008-02-08 | 2011-11-25 | Prosensa Holding Bv | Methods and means for treating dna repeat instability associated genetic disorders |
| AU2009246053B2 (en) | 2008-05-14 | 2014-07-24 | Agriculture Victoria Services Pty Ltd. | Use of angiogenin or angiogenin agonists for treating diseases and disorders |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| AU2009262970A1 (en) * | 2008-06-26 | 2009-12-30 | Acceleron Pharma Inc. | Methods for dosing an activin-ActRIIa antagonist and monitoring of treated patients |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| SMT202300222T1 (it) * | 2008-08-14 | 2023-09-06 | Acceleron Pharma Inc | Trappole di gdf |
| KR20110084280A (ko) | 2008-11-03 | 2011-07-21 | 알레시아 바이오쎄라퓨틱스 인코포레이티드 | 종양 항원의 생물 활성을 특이적으로 차단하는 항체 |
| US8138142B2 (en) * | 2009-01-13 | 2012-03-20 | Acceleron Pharma Inc. | Methods for increasing adiponectin in a patient in need thereof |
| CA2759899A1 (en) | 2009-04-24 | 2010-10-28 | Prosensa Technologies B.V. | Oligonucleotide comprising an inosine for treating dmd |
| BRPI1010587A2 (pt) * | 2009-06-08 | 2019-04-09 | Acceleron Pharma Inc. | métodos para aumentar adipócitos termogênicos |
| EP2440577A4 (en) | 2009-06-12 | 2013-01-23 | Acceleron Pharma Inc | SHORTEN ACTRIIB FC FUSION PROTEINS |
| BR112012005225B8 (pt) * | 2009-09-09 | 2023-01-10 | Acceleron Pharma Inc | Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente |
| EP3818988A1 (en) * | 2009-11-03 | 2021-05-12 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
| TW201120210A (en) | 2009-11-05 | 2011-06-16 | Hoffmann La Roche | Glycosylated repeat-motif-molecule conjugates |
| JP6267425B2 (ja) * | 2009-11-17 | 2018-01-24 | アクセルロン ファーマ， インコーポレイテッド | 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用 |
| WO2011078672A1 (en) | 2009-12-24 | 2011-06-30 | Prosensa Technologies B.V. | Molecule for treating an inflammatory disorder |
| EP2606119A1 (en) | 2010-08-20 | 2013-06-26 | Wyeth LLC | Cell culture of growth factor-free adapted cells |
| CN103298832A (zh) | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
| RS59080B1 (sr) | 2011-03-31 | 2019-09-30 | Adc Therapeutics Sa | Antitela protiv antigena 1 povezanog sa bubrezima i njihovi fragmenti koji se vezuju za antigen |
| US20140322758A1 (en) | 2011-10-21 | 2014-10-30 | Pfizer Inc. | Addition of iron to improve cell culture |
| HRP20190946T1 (hr) | 2012-01-09 | 2019-07-26 | Adc Therapeutics Sa | Sredstva za liječenje trostruko negativnog raka dojke |
| CN112251436A (zh) | 2012-01-27 | 2021-01-22 | 比奥马林技术公司 | 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸 |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| AU2013204740C1 (en) | 2012-05-10 | 2015-10-01 | Agriculture Victoria Services Pty Ltd | Methods of treating cancer using angiogenin or an angiogenin agonist |
| WO2014000042A1 (en) * | 2012-06-27 | 2014-01-03 | Prince Henry's Institute Of Medical Research | COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS |
| ES3047691T3 (en) | 2012-08-01 | 2025-12-04 | Ikaika Therapeutics Inc | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4) |
| EP2906683B1 (en) | 2012-10-15 | 2017-05-31 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| AU2013334660B2 (en) | 2012-10-24 | 2018-08-09 | Celgene Corporation | Methods for treating anemia |
| CN104968801B (zh) * | 2012-10-24 | 2021-06-15 | 细胞基因公司 | 用于治疗贫血症的生物标志物 |
| NZ707477A (en) | 2012-11-02 | 2019-09-27 | Celgene Corp | Activin-actrii antagonists and uses for treating bone and other disorders |
| CA2899170C (en) | 2013-01-30 | 2022-08-02 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| JP6143270B2 (ja) * | 2013-01-31 | 2017-06-07 | 学校法人東京薬科大学 | マイオスタチン阻害ペプチド |
| EP2983694B1 (en) | 2013-04-08 | 2022-06-22 | President and Fellows of Harvard College | Compositions for rejuvenating skeletal muscle stem cells |
| EP3881859B1 (en) * | 2013-06-11 | 2024-03-06 | President and Fellows of Harvard College | Compositions for increasing neurogenesis and angiogenesis |
| TWI648401B (zh) * | 2013-07-31 | 2019-01-21 | 安美基公司 | 生長分化因子１５（ｇｄｆ－１５）構築體 |
| CN104725513A (zh) * | 2013-12-20 | 2015-06-24 | 中国科学院上海生命科学研究院 | 融合蛋白及其在治疗多发性硬化中的用途 |
| WO2015192111A1 (en) | 2014-06-13 | 2015-12-17 | Acceleron Pharma, Inc. | Methods and compositions for treating ulcers |
| MX370115B (es) | 2014-07-30 | 2019-12-02 | Ngm Biopharmaceuticals Inc | Dímeros que comprenden dos polipéptidos, útiles en el tratamiento de trastornos metabólicos. |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| PL3212226T3 (pl) | 2014-10-31 | 2020-11-02 | Ngm Biopharmaceuticals, Inc. | Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych |
| JP2018501307A (ja) | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| CA3010799A1 (en) * | 2016-01-06 | 2017-07-13 | President And Fellows Of Harvard College | Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis |
| PE20190126A1 (es) | 2016-03-31 | 2019-01-17 | Ngm Biopharmaceuticals Inc | Proteinas de union y metodos de uso de las mismas |
| CA3124415A1 (en) | 2018-12-21 | 2020-06-25 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
| US20220062299A1 (en) | 2018-12-26 | 2022-03-03 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| DE3382562D1 (de) | 1982-09-24 | 1992-06-25 | Us Health | Wiederherstellung von gewebe bei tieren. |
| US4588684A (en) | 1983-04-26 | 1986-05-13 | Chiron Corporation | a-Factor and its processing signals |
| NZ210699A (en) | 1984-01-04 | 1989-06-28 | Int Genetic Eng | Isolation of an osteogenic protein of the p3 immunologically related family |
| ZA848495B (en) | 1984-01-31 | 1985-09-25 | Idaho Res Found | Production of polypeptides in insect cells |
| CA1341617C (en) * | 1984-06-08 | 2011-06-28 | Henry George Burger | Inhibin isolated from ovarian follicular fluid |
| NZ228031A (en) | 1984-07-06 | 1991-12-23 | Sandoz Ltd | Primate gm-csf and method of extraction |
| DE3588058T3 (de) | 1984-07-16 | 2005-04-07 | Celtrix Pharmaceuticals, Inc., Palo Alto | Knorpel-induzierende Polypeptid-Faktoren aus Knochen |
| US4740587A (en) | 1985-07-18 | 1988-04-26 | The Salk Institute For Biological Studies | Inhibin and method of purifying same |
| US5089396A (en) * | 1985-10-03 | 1992-02-18 | Genentech, Inc. | Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid |
| NZ217727A (en) | 1985-10-03 | 1990-05-28 | Genentech Inc | Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it |
| US5215893A (en) * | 1985-10-03 | 1993-06-01 | Genentech, Inc. | Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid |
| US4798885A (en) * | 1986-02-07 | 1989-01-17 | Genentech, Inc. | Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain |
| US4737578A (en) * | 1986-02-10 | 1988-04-12 | The Salk Institute For Biological Studies | Human inhibin |
| US5187076A (en) * | 1986-07-01 | 1993-02-16 | Genetics Institute, Inc. | DNA sequences encoding BMP-6 proteins |
| ZA874681B (en) * | 1986-07-01 | 1988-04-27 | Genetics Inst | Novel osteoinductive factors |
| IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| US5106748A (en) * | 1986-07-01 | 1992-04-21 | Genetics Institute, Inc. | Dna sequences encoding 5 proteins |
| US5013649A (en) * | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
| US5041538A (en) * | 1987-08-28 | 1991-08-20 | The Salk Institute For Biological Studies | Mammalian follistatin |
| AU645244B2 (en) | 1988-04-08 | 1994-01-13 | Genetics Institute, Llc | Bone and cartilage inductive compositions |
| US5071834A (en) * | 1988-09-16 | 1991-12-10 | Genentech, Inc. | Purified activin B composition |
| DE69031939T2 (de) | 1989-03-28 | 1998-09-10 | Genetics Institute, Inc., Cambridge, Mass. | Osteoinduktive zusammensetzungen |
| EP0394827A1 (en) * | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
| CA2020729A1 (en) | 1989-07-19 | 1991-01-20 | Michael C. Kiefer | Bone morphogenetic protein |
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| US5116944A (en) * | 1989-12-29 | 1992-05-26 | Neorx Corporation | Conjugates having improved characteristics for in vivo administration |
| US5166190A (en) | 1990-01-08 | 1992-11-24 | Genentech, Inc. | Method for increasing fertility in males |
| JPH06500991A (ja) | 1990-05-16 | 1994-01-27 | ジェネティックス・インスティテュート・インコーポレイテッド | 骨および軟骨誘導蛋白質 |
| EP0550625B1 (en) | 1990-09-26 | 2003-11-05 | Genetics Institute, LLC | Bmp-5 derivatives |
| EP0513334A4 (en) | 1990-11-30 | 1993-08-04 | Celtrix Laboratories, Inc. | Use of a bone morphogenetic protein in synergistic combination with tgf--g(b) for bone repair |
| US5208219A (en) * | 1991-02-14 | 1993-05-04 | Celtrix Pharmaceuticals Inc. | Method for inducing bone growth |
| US6162896A (en) * | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
| JPH07500315A (ja) | 1991-05-10 | 1995-01-12 | セルトリックス ファーマシューティカルズ，インコーポレイテッド | 骨成長因子の標的送達 |
| AU652472B2 (en) | 1991-06-25 | 1994-08-25 | Genetics Institute, Llc | BMP-9 compositions |
| DE69226871T3 (de) * | 1991-06-27 | 2009-09-24 | Bristol-Myers Squibb Co. | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
| US5171579A (en) * | 1991-10-11 | 1992-12-15 | Genetics Institute, Inc. | Formulations of blood clot-polymer matrix for delivery of osteogenic proteins |
| ATE238417T1 (de) | 1991-11-04 | 2003-05-15 | Inst Genetics Llc | Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung |
| EP0653942B2 (en) | 1992-07-31 | 2007-03-07 | Curis, Inc. | Morphogen-induced nerve regeneration and repair |
| US6465239B1 (en) * | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
| US5994618A (en) * | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| US20030074680A1 (en) * | 1993-03-19 | 2003-04-17 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| US7393682B1 (en) * | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US6673534B1 (en) * | 1995-10-26 | 2004-01-06 | The Johns Hopkins University School Of Medicine | Methods for detection of mutations in myostatin variants |
| DK0690873T3 (da) | 1993-03-19 | 2003-09-29 | Univ Johns Hopkins Med | Vækstdifferentieringsfaktor-8 |
| US6607884B1 (en) * | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
| BR9406715A (pt) | 1993-05-12 | 1996-02-06 | Genetics Inst | Molécula de DNA isolada célula hospedeira vetor método para produzir uma proteina (BMP-11) polipeptideo de proteina-11 morfogenética de osso purificada (BMP-11) e molécula de DNA quimérica |
| DK0716610T3 (da) * | 1993-08-26 | 2006-09-04 | Genetics Inst Llc | Humane knogle-morfogenetiske proteiner til anvendelse ved neural regenerering |
| US7332575B2 (en) * | 1994-03-18 | 2008-02-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species |
| CA2194660C (en) | 1994-07-08 | 2009-09-29 | Se-Jin Lee | Growth differentiation factor-11 |
| US6008434A (en) | 1994-07-08 | 1999-12-28 | Johns Hopkins University School Of Medicine | Growth differentiation factor-11 transgenic mice |
| US5466190A (en) * | 1994-07-25 | 1995-11-14 | Deere & Company | Precleaner for a cleaning shoe |
| US5545616A (en) * | 1994-09-22 | 1996-08-13 | Genentech, Inc. | Method for predicting and/or preventing preterm labor |
| JPH10262688A (ja) * | 1994-11-30 | 1998-10-06 | Univ Rockefeller | 体重のモジュレーター、対応する核酸およびタンパク質、ならびにそれらの診断および治療用途 |
| US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| KR20000064752A (ko) | 1996-03-22 | 2000-11-06 | 더 제네랄 호스피탈 코포레이션 | 중추신경계허혈또는외상의발현후폴리펩티드성장인자를투여하는방법 |
| US6696557B1 (en) * | 1996-04-19 | 2004-02-24 | Genentech, Inc. | AL-2 neurotrophic factor nucleic acid |
| AR008077A1 (es) * | 1996-07-26 | 1999-12-09 | Talarico Salinas Laura Beatriz | Un polipeptido de fusion o una sal del mismo, su uso, un proceso para prepararlos, una composicion farmaceutica que los comprende, y un vector. |
| WO1998033887A1 (en) | 1997-02-05 | 1998-08-06 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| DE69841139D1 (de) * | 1997-07-14 | 2009-10-22 | Univ Liege | Mutationen im myostatingen steigern muskelmasse in säugetieren |
| US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6696260B1 (en) * | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| US6656475B1 (en) * | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| AU8666398A (en) | 1997-08-01 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Methods to identify growth differentiation factor (gdf) receptors |
| GB2345397B (en) * | 1997-08-19 | 2001-10-31 | Citizen Watch Co Ltd | Piezoelectric vibrator |
| US6372454B2 (en) | 1997-08-29 | 2002-04-16 | Human Genome Sciences, Inc. | Nucleic acid molecules encoding Follistatin-3 |
| AU1276399A (en) * | 1997-11-07 | 1999-05-31 | Genetics Institute Inc. | Neuronal uses of bmp-11 |
| WO1999024618A1 (en) | 1997-11-10 | 1999-05-20 | The Johns Hopkins University School Of Medicine | Methods for detection of mutations in myostatin variants |
| WO1999040181A1 (en) | 1998-02-05 | 1999-08-12 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
| US6004937A (en) | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
| ES2330062T3 (es) | 1998-05-06 | 2009-12-03 | Metamorphix, Inc. | Procedimientos para tratar la diabetes por inhibicion de gdf-8. |
| US6660499B1 (en) * | 1998-08-20 | 2003-12-09 | Regeneron Pharmaceuticals, Inc. | DCR5, a BMP-binding protein, and applications thereof |
| AU772694B2 (en) * | 1999-01-21 | 2004-05-06 | Metamorphix International, Inc. | Growth differentiation factor inhibitors and uses therefor |
| JP2003502292A (ja) * | 1999-06-01 | 2003-01-21 | バイオジェン インコーポレイテッド | ヘッジホッグタンパク質のポリマー結合体及び利用 |
| US7056512B1 (en) | 1999-07-20 | 2006-06-06 | Pharmexa A/S | Method for down-regulating GDF-8 activity |
| WO2001064888A2 (en) | 2000-02-29 | 2001-09-07 | Zymogenetics, Inc. | Kunitz domain polypeptide zkun8 |
| US7037501B2 (en) * | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
| TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| PL350983A1 (en) * | 2001-11-30 | 2003-06-02 | Advanced Digital Broadcast Ltd | Method of scanning a high-frequency signal band and apparatus therefor |
| BR0307871A (pt) * | 2002-02-21 | 2005-04-12 | Wyeth Corp | Proteìnas contendo domìnio de folistatina |
| CA2476887A1 (en) * | 2002-02-21 | 2003-09-04 | Wyeth | Gasp1:a follistatin domain containing protein |
| EP2192129A1 (en) * | 2002-09-16 | 2010-06-02 | Johns Hopkins University | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| CN101287484B (zh) | 2002-12-20 | 2012-10-10 | 安姆根有限公司 | 抑制肌肉生长抑制素的结合剂 |
| BRPI0410927A (pt) | 2003-06-02 | 2006-06-27 | Wyeth Corp | métodos terapêuticos e profiláticos para distúrbios neuromusculares |
| AU2006232914A1 (en) | 2005-03-23 | 2006-10-12 | Wyeth | Detection of an immune response to GDF-8 modulating agents |
| CA2601667A1 (en) * | 2005-03-23 | 2006-09-28 | Wyeth | Detection of gdf-8 modulating agents |
-
2002
- 2002-02-07 TW TW091102268A patent/TWI329129B/zh not_active IP Right Cessation
- 2002-02-07 TW TW094108366A patent/TW200526779A/zh unknown
- 2002-02-08 NZ NZ527286A patent/NZ527286A/en not_active IP Right Cessation
- 2002-02-08 AT AT02709366T patent/ATE357519T1/de active
- 2002-02-08 CA CA002437218A patent/CA2437218A1/en not_active Abandoned
- 2002-02-08 SG SG200506783-0A patent/SG165982A1/en unknown
- 2002-02-08 CA CA002674673A patent/CA2674673A1/en not_active Abandoned
- 2002-02-08 MX MXPA03007063A patent/MXPA03007063A/es active IP Right Grant
- 2002-02-08 BR BR0207110-0A patent/BR0207110A/pt not_active IP Right Cessation
- 2002-02-08 ES ES02709366T patent/ES2284828T3/es not_active Expired - Lifetime
- 2002-02-08 WO PCT/US2002/003467 patent/WO2002068650A2/en not_active Ceased
- 2002-02-08 AR ARP020100421A patent/AR032567A1/es not_active Application Discontinuation
- 2002-02-08 JP JP2002568744A patent/JP4280071B2/ja not_active Expired - Fee Related
- 2002-02-08 SG SG2010040194A patent/SG187989A1/en unknown
- 2002-02-08 ZA ZA200508954A patent/ZA200508954B/en unknown
- 2002-02-08 AU AU2002243852A patent/AU2002243852B2/en not_active Ceased
- 2002-02-08 DK DK02709366T patent/DK1397492T3/da active
- 2002-02-08 PL PL390369A patent/PL212078B1/pl unknown
- 2002-02-08 EP EP02709366A patent/EP1397492B1/en not_active Expired - Lifetime
- 2002-02-08 NZ NZ550297A patent/NZ550297A/en not_active IP Right Cessation
- 2002-02-08 US US10/071,499 patent/US7202210B2/en not_active Expired - Fee Related
- 2002-02-08 DE DE60219006T patent/DE60219006T2/de not_active Expired - Lifetime
- 2002-02-08 PL PL372888A patent/PL207202B1/pl unknown
- 2002-02-08 PT PT02709366T patent/PT1397492E/pt unknown
-
2003
- 2003-08-04 NO NO20033456A patent/NO333427B1/no not_active IP Right Cessation
- 2003-08-06 ZA ZA200306064A patent/ZA200306064B/en unknown
-
2005
- 2005-07-19 JP JP2005209321A patent/JP2006001938A/ja not_active Withdrawn
-
2006
- 2006-12-21 US US11/614,594 patent/US7560441B2/en not_active Expired - Fee Related
- 2006-12-21 US US11/614,702 patent/US7737116B2/en not_active Expired - Fee Related
-
2007
- 2007-05-29 CY CY20071100719T patent/CY1106629T1/el unknown
-
2008
- 2008-11-21 JP JP2008298812A patent/JP5013618B2/ja not_active Expired - Fee Related
-
2009
- 2009-03-18 CL CL2009000648A patent/CL2009000648A1/es unknown
- 2009-05-04 US US12/434,758 patent/US8222384B2/en not_active Expired - Fee Related
-
2012
- 2012-06-14 US US13/523,391 patent/US8710025B2/en not_active Expired - Fee Related
-
2013
- 2013-09-19 US US14/032,079 patent/US20140228289A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005507637A5 (https=) | ||
| JP2005534616A5 (https=) | ||
| US20230312696A1 (en) | Compositions and Methods of Use for Treating Metabolic Disorders | |
| JP4988599B2 (ja) | Ｉｇｆ−１融合ポリペプチドおよびその治療的使用 | |
| CN103547590B (zh) | 高度可溶性瘦蛋白 | |
| JP4659068B2 (ja) | Ｏｂ融合タンパク質組成物および方法 | |
| EP2507267B1 (en) | Compositions and methods for increasing serum half-life of fc fusion proteins | |
| JP6923115B2 (ja) | 高グリコシル化ヒト血液凝固第ｖｉｉｉ因子の融合タンパク質、その調製方法、および使用 | |
| CN102816242B (zh) | 在体内具有延长的半衰期和增强的红细胞生成活性的重组人EPO‑Fc融合蛋白 | |
| CN103957926B (zh) | 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽 | |
| JP7046903B2 (ja) | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 | |
| WO2002068650B1 (en) | Modified and stabilized gdf propeptides and uses thereof | |
| EA019203B1 (ru) | Коагонисты глюкагонового рецептора/glp-1-рецептора | |
| JP7702445B2 (ja) | 免疫調節融合タンパク質 | |
| JPH11505109A (ja) | Ｏｂ蛋白の生物学的活性ペプチドフラグメント | |
| JP2009510999A (ja) | キメラ治療剤 | |
| JP2008502301A (ja) | ペプチドの抱合 | |
| JP2022118184A (ja) | コンジュゲートされたｃ１エステラーゼインヒビター及びその使用 | |
| JP2002512199A5 (https=) | ||
| CN116635050A (zh) | 对胰高血糖素、glp-1和gip受体全部具有活性的新型三重激动剂及其用途 | |
| CN106279430B (zh) | Exendin‑4类似物融合蛋白及其制备方法和用途 | |
| TW202140074A (zh) | Fgf-21結合物調配物 | |
| JP2005519946A (ja) | 発作の処置のためのインターフェロンβ様分子 | |
| KR19980064258A (ko) | 항비만 단백질 | |
| JP2012065656A (ja) | Ｉｇｆ−１融合ポリペプチドおよびその治療的使用 |